Table 3:
H2O2, tBOOH and IAA Toxicity
| Compound | H2O2 (750 nM) | tBOOH (5 μM) | IAA (15 μM) |
|---|---|---|---|
| No treatment | 4.3 ± 5.6% | 5.5 ± 2.0% | 4.1 ± 4.3% |
| Ferrostatin (10 μM) | 22.4 ± 23% | 58.4 ± 3.0%**** | 83.0 ± 4.2%**** |
| Liproxstatin (1 μM) | 19.9 ± 22% | 59.6 ± 6.2%**** | 74.5 ± 3.4%**** |
| Deferiprone (100 μM) | 86.5 ± 23.1%**** | 78.4 ± 12.4%**** | 92.0 ± 2.5%**** |
| MitoQ (1 μM) | 0% | 88.5 ± 7.1%**** | 5.5 ± 3.3% |
| Clorgyline (100 μM) | 0% | 27.4 ± 11.5% | 14.0 ± 4.0% |
| 968 (10 μM) | 0% | 11.4 ± 19.7% | 80.5 ± 5.7%**** |
| GSK2795039 (10 μM) | 0% | 3.4 ± 5.7% | 76.4 ± 4.0%**** |
| GKT137831 (10 μM) | 1.8 ± 3.2% | 2.9 ± 3.4% | 74.2 ± 2.8%**** |
| PD146176 (5 μM) | 0% | 4.4 ± 6.1% | 79.8 ± 7.0%**** |
| Troglitazone (1 μM) | 0% | 24.2 ± 4.3% | 55.5 ± 0.6%**** |
| Idebenone (1 μM) | 0% | 0% | 78.7 ± 4.3%**** |
| CoCl2 (100 μM) | 56.6 ± 5.2%**** | 18.0 ± 4.1% | 34.1 ± 14.3%**** |
| LY83583 (1 μM) | 0% | 0% | 0% |
| Apomorphine (5 μM) | 0% | 0% | 79.0 ± 3.5%**** |
| BI-6C9 (10 μM) | 0% | 0% | 72.9 ± 2.2%**** |
| Bafilomycin (100 nM) | 25.0 ± 2.0% | 74.4 ± 1.3%**** | 73.8 ± 3.2%**** |
| Scriptaid (10 μM) | 0% | 71.4 ± 6.9%**** | 72.7 ± 2.4%**** |
| Nullscript (10 μM) | 0% | 20.5 ± 8.0% | 59.5 ± 7.5%**** |
| Flt3 inhibitor (1 μM) | 24.6 ± 2.8% | 58.2 ± 8.7%**** | 78.2 ± 6.7%**** |
The oxytosis/ferroptosis inhibitors that were effective against glutamate, erastin and RSL3 as shown in Table 1 were tested for their ability to protect mouse HT22 hippocampal cells against H2O2, tBOOH and IAA toxicity at doses that induce 85%-95% cell death. The inhibitor concentrations that were most effective in the studies shown in Table 1 were used. The values presented are the average of a minimum of three independent experiments with all treatments done in triplicate.
****
p<0.0001 versus H2O2, tBOOH or IAA alone.